Transcriptomics to study the effect of a Mediterranean-inspired diet on inflammation in Crohn's disease patients
© Marlow et al.; licensee BioMed Central Ltd. 2013
Received: 2 October 2013
Accepted: 16 November 2013
Published: 27 November 2013
Inflammation is an essential immune response; however, chronic inflammation results in disease including Crohn's disease. Therefore, reducing the inflammation can yield a significant health benefit, and one way to achieve this is through diet. We developed a Mediterranean-inspired anti-inflammatory diet and used this diet in a 6-week intervention in a Crohn's disease population. We examined changes in inflammation and also in the gut microbiota. We compared the results of established biomarkers, C-reactive protein and the micronuclei assay, of inflammation with results from a transcriptomic approach.
Data showed that being on our diet for 6 weeks was able to reduce the established biomarkers of inflammation. However, using transcriptomics, we observed significant changes in gene expression. Although no single gene stood out, the cumulative effect of small changes in many genes combined to have a beneficial effect. Data also showed that our diet resulted in a trend of normalising the microbiota.
This study showed that our Mediterranean-inspired diet appeared to benefit the health of people with Crohn's disease. Our participants showed a trend for reduced markers of inflammation and normalising of the microbiota. The significant changes in gene expression after 6 weeks highlighted the increased sensitivity of using transcriptomics when compared to the established biomarkers and open up a new era of dietary intervention studies.
KeywordsInflammation Crohn's disease Transcriptomics Dietary intervention
Nutrigenomics studies the effect of a specific food or diet on gene and expression using the omic technologies. This will lead to a better understanding of the mechanism of how specific dietary components affect specific gene and proteins resulting in an understanding of how metabolism is influenced .
Determining the effects of intervention studies can be difficult, as the change in gene expression for an individual gene may be low but the number of genes affected could be large, resulting in a cumulative beneficial effect as a result of the intervention. Such trials are costly and time consuming and have required a prior hypothesis and ideally pilot data before commencement, to ensure that the correct genes were measured. The technology of transcriptomics has allowed non-hypothesis-based studies to be undertaken. This technique allows the study of thousands of genes simultaneously, and the sensitivity allows the detection of a small change in the expression of a gene. The other advantage of such a sensitive technique is that the results allow intervention trials to be conducted over a much shorter time frame and with fewer participants. The non-hypothesis-based approach and the reduced cost of a shorter smaller trial would allow smaller food companies to prove efficacy of functional foods or novel diets and thus make a substantiated health claim.
Inflammation is a necessary immune response; however, chronic inflammation can lead to chronic diseases including cardiovascular disease, rheumatoid arthritis, Alzheimer's, Crohn's disease and even some cancers [2–4]. Therefore, reducing the inflammation can yield a significant health benefit [2, 5, 6]. Crohn's disease is a chronic intestinal disorder, typified by chronic inflammation of the gastrointestinal tract. While it has a clear genetic susceptibility, lifestyle factors including diet are important factors in disease development [7–9]. If diet is a cause of symptoms, then it stands to reason that diet can also relieve symptoms, and therefore, Crohn's disease would be a good target for nutrigenomics [1, 10].
As Crohn's disease is localised to the gastrointestinal tract, one would expect to find dysbiosis of the intestinal microbiome [11–13]. The interplay between diet, intestinal microbiota, genetics and health is complex . In recent years, the role of the microbiota has become of greater importance in understanding human health and disease. Six bacterial phyla, comprising over 1,000 species, have been identified as the predominant inhabitants of the human gut [15, 16]. While previously considered a static entity, it is now emerging that the ratio of the bacterial phyla and species in the gut is constantly changing in response to external influences like diet. Different diseases also have a deviation from what is being considered a 'normal’ ratio of bacterial phyla . Whether change to the microbiota is a cause or effect of disease is currently unknown.
The relative abundance of bacteria in a healthy and Crohn's disease microbiome
'Healthy’ microbiome (%)
'Crohn's disease’ microbiome
Decreased expression in Clostridium clusters IV and XIVa and increased expression in Bacillus
Adherence to the diet
All eight participants completed the 6-week diet and in a self-reported questionnaire felt they adhered to the diet well. Based on participant responses to the food diaries, we were able to show that the average total energy consumption reduced from 8,189 to 6,716 kJ, and cholesterol levels were reduced by 20%. There was also a reduction in average intake of saturated fat (43.9% to 32.1%) and a corresponding increase in mono- (38.9% to 46.6%) and poly-unsaturated fats (17% to 21.1%).
Key functions associated with dietary intervention
Number of genes
Diseases and disorders
8.67E - 09 to 9.70E - 03
Skeletal and muscular disorders
8.67E - 09 to 7.60E - 03
8.67E - 08 to 1.41E - 02
1.27E - 05 to 9.70E - 03
1.37E - 05 to 1.37E - 02
Molecular and cellular function
Cellular growth and proliferation
1.23E - 07 to 1.47E - 02
1.81E - 07 to 1.40E - 02
9.24E - 07 to 1.24E - 02
Cell-to-cell signalling and interaction
1.76E - 06 to 1.46E - 02
1.76E - 06 to 1.37E - 02
Physiological system development and function
Hematological system development and function
1.76E - 06 to 1.40E - 02
Immune cell trafficking
1.76E - 06 to 1.24E - 02
1.76E - 06 to 1.46E - 02
3.81E - 06 to 3.81E - 06
Cardiovascular system development and function
3.90E - 06 to 1.32E - 02
Key canonical pathways affected by intervention
4.24E - 04
B cell development
9.31E - 04
T helper cell differentiation
3.55E - 03
Uracil degradation II (reductive)
7.6E - 03
7.6E - 03
When combining all data from Crohn's disease participants (n = 8) and making pre- and post-diet comparisons of each bacterial cluster, there is a forward trend, yet no significant improvement in the expression of the bacteria that were known to have an altered relative abundance in Crohn's disease (Figure 5). There was an increase in the expression of Bacteroidetes (17.89% to 18.74%), Clostridium cluster IV (19.2% to 21.86%) and Clostridium cluster XIVa (26.78% to 28.79%) and a decrease in the abundance of Proteobacteria (5.93% to 5.48%) and Bacillaceae (4.65% to 4.21%).
As previously stated, inflammation can cause chronic disease; therefore, it is important to identify and reduce inflammation, one such way is through diet. We found that in this pilot study, there was a small reduction in the established biomarkers of inflammation after consuming our diet for 6 weeks. Using the transcriptomic approach, we did see significant changes in gene expression. In total, we found 3,551 genes that were differentially expressed in our study as a result of a 6-week dietary intervention. The most common candidates were not the genes that were affected, and although results for individual genes were not spectacular, it is the combination of affected genes that is interesting. The data highlighted the difference in sensitivity between the established biomarkers and the transcriptomic approach and confirmed that conducting a short-term trial with a small number of participants is feasible.
The patients who volunteered for this study were selected based on strict criteria. Several of them already used diet as a way of controlling symptoms and so for transcriptomics to still show an effect highlights how sensitive this technique is. This increased sensitivity allows for short-term studies with fewer study numbers than traditional trials to be performed, which has significant implications for future human clinical trials.
The ratio of the six bacterial phyla or families from the faecal microbiome of healthy individuals has been determined. It is well documented that deviation from this 'norm’ occurs in individuals who have Crohn's disease. Normalising the intestinal microbiota through diet is a step towards potentially reducing inflammation and thus restoring health and improving the quality of life for people with Crohn's disease.
After 6 weeks on our Mediterranean-inspired diet, there was some 'normalising’ of the intestinal microbiota. As previously stated, the participants were already managing their disease through diet, so the expression of the microbiota was not too dissimilar from that documented in a healthy group. However, as a group, the microbiota before the diet was tending towards that expected for people with Crohn's disease, notably a reduction in the presence of Bacteroidetes and an increase in the presence of Proteobacteria and Bacillaceae.
Consuming the Mediterranean-inspired anti-inflammatory diet for 6 weeks was able to influence the intestinal microbiota of our study population, although this improvement should be noted as a forward trend rather than any statistically significant change. There was an observed increase in Bacteroidetes and the Clostridium clusters and a decrease in Protebacteria and Bacillaceae.
One of the aims of this pilot study was to compare the data obtained from traditional biomarkers of inflammation with that of transcriptomics. The Affymetrix GeneChip® PrimeView™ arrays were selected as they provide complete coverage of the human genome. We were impressed by the increased sensitivity provided by the arrays over the biomarkers.
Peripheral blood mononuclear cells (PBMCs) can be easily obtained from a venepuncture, which allows for easy and repeated collection unlike biopsies of other tissues . PBMCs have been used to examine gene expression in numerous diseases including inflammation [39–45] and have also been shown to act as a biomarker of nutritional interventions [22, 46, 47] and used to predict inflammatory response to functional foods . The increased sensitivity of transcriptomics and the fact that PBMCs can be used as a model to study the expression of inflammatory genes  make this methodology attractive for non-hypothesis-based studies.
One of the drawbacks of this study was the small study population, which resulted in observing a trend in effect of the diet rather than significant results. However, one of the benefits of using transcriptomics is the ability to conduct dietary interventions over a shorter time frame and requiring fewer subject numbers. This subsequently reduce costs which will open up the area of health-based food claims to a wider market, meaning that more companies and more products could be tested. This could lead to a better understanding of the mechanism of action and thus substantiated health claims benefiting both the companies and the population.
The data from this pilot study, although not significant, does highlight that by choosing an anti-inflammatory diet, even for a short time, can have an effect on reducing inflammatory markers, changing gene expression and normalising the microbiota.
This study was granted ethical approval by the Northern Regional Ethics Committee of New Zealand (reference NTY/11/11/109). Requirements for inclusion in the study were very strict and were intentionally so given the aetiology of Crohn's disease and the potential bias from medication and surgical interventions. Selection criteria included the following: had no bowel surgery, was not taking prednisone or similar anti-inflammatory medication, had no changes to their medication over the last 3 months, indicating a stable condition, were willing to provide samples at the beginning and end of the study and were willing to change their diet. This was self-reported by the participants.
All participants consumed the Mediterranean-inspired anti-inflammatory diet for 6 weeks. They were provided with food items including salmon, organic avocados, kumara, a variety of vegetables, gluten-free bread, New Zealand extra virgin olive oil, green tea, honey and fish oil capsules. The majority of these foods were grown and produced in New Zealand and were used to supplement the participant's diet. A reduction in the consumption of red meat, white flour, high-fat foods and sugar was also expected. All participants provided a blood and faecal sample at the beginning and end of the study and completed food diaries.
Eight participants, from Auckland, New Zealand, who had active yet stable Crohn's disease symptoms and passed the selection criteria (see above) were selected to participate following an initial invitation to all Crohn's disease participants in the Diet and Gene Database administered by Nutrigenomics New Zealand.
Our participants were six females and two males, aged between 31 and 60 years (mean age 45.4 years), and the length of time since diagnosis with Crohn's disease ranged from 7 to 36 years.
Levels of C-reactive protein, a systemic measure of inflammation  and changes in DNA damage in peripheral blood lymphocyte cells by the micronucleus assay (in accordance with OECD guidelines 487) were scored before and after the diet, along with comparisons of RNA gene expression profiles.
A blood sample collected in serum-separating tubes was analysed for C-reactive protein. C-reactive protein is found in the blood in response to inflammation and is a biomarker for potential disease development. Specimens were analysed by a medical testing laboratory, Labtests Auckland, according to their protocols for the latex-enhanced immunoturbidimetric assay.
DNA damage—micronucleus assay
The cytokinesis-block micronucleus assay , a validated method for determining DNA damage in peripheral blood lymphocytes cells, was used to observe any changes in DNA damage before and after the diet intervention. DNA damage was determined by the presence of micronuclei (MN) in the cytoplasm of bi-nucleated lymphocyte cells. Whole blood treated with anticoagulant (heparin) was collected, stored at room temperature and cultured within 24 h. Duplicate cultures containing 0.6 ml whole blood and 9.25 ml alpha MEM and 15% foetal calf serum (Gibco New Zealand Ltd., Auckland, New Zealand) were prepared, to which 150 μl phytohaemaglutinin (PHA, Gibco New Zealand Ltd.) was added to stimulate lymphocyte replication. The cells were incubated in a humidified incubator containing 5% carbon dioxide for 44 h. Cytochalasin B (Sigma Chemical Co., St. Louis, MO, USA) was added to give a final concentration of 4.5 μg/ml, and the culture was incubated for an additional 26 h. The cytochalasin B would halt any further cell growth. Cells were harvested using standard protocols as outlined , including centrifugation, swelling of the cells using hypotonic KCl and fixing in a solution of methanol and acetic acid before dropping onto slides. Once dried, the slides were stained with Diff-Quik (Dade Behring Inc., Sacramento, CA, USA) according to staining protocols. Two thousand bi-nucleated cells were scored for micronuclei using the criteria outlined by Heddle et al.  and Fenech .
RNA isolation and storage
Whole blood was collected in a PAXgene Blood RNA Tube (PBRT) (PreAnalytiX) following the manufacturer's recommended protocol. The blood was incubated at room temperature for 2 h, after collection to improve RNA yield, before being stored at -70°C.
RNA extraction was performed according to the recommended protocol PAXgene Blood RNA System Kit (Qiagen). The quantity of RNA was determined using the NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) and the quality of RNA by the Experion RNA StdSens Analysis Kit (Biorad, Hercules, CA, USA). For successful gene expression microarray hybridization, a concentration of >100 ng/μl of RNA and a RNA quality indicator (RQI) of >8 are required.
Gene expression arrays
Microarray hybridization was performed on GeneChip® PrimeView™ Human Gene Expression arrays (Affymetrix) following the manufacturer's protocol by The Ramaciotti Centre, University of New South Wales, Sydney, Australia, using the Affymetrix GeneChip® Instrument System.
Gene expression data analysis
Affymetrix Primeview array data was read using the 'affy’ package in the statistical language R and normalised using the RMA method. QA of the data showed that it was of good quality and free of obvious artifacts or outliers. The 'limma’ package was used to compare gene expression pre- and post-diet, paired by participant code.
Further analyses of the differentially expressed genes, including network, pathway and functional analysis, were carried out using IPA (Ingenuity Systems Inc., USA; http://www.ingenuity.com).
A faecal sample was provided by each study participant before and after the diet. The samples were frozen at -80°C until required for analysis. Total DNA from the faecal matter was extracted according to the protocol published by Candela et al.  in combination with the DNAeasy Blood and Tissue Kit 50 (Qiagen). The final DNA concentration and purity were determined using the NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies). The extracted DNA was standardised to 50 ng/μl and stored at -20°C. These samples were then sent to the Department of Pharmaceutical Science, University of Bologna, Italy for analysis. The amplification and purification of DNA and the subsequent HTF-Microbi.Array were conducted according to protocols defined by Candela et al. . Briefly, amplification of the DNA by PCR was achieved using 16 s rDNA sequencing, facilitated by Taq polymerase (Promega, Madison, WI, USA) and the universal forward primer f27 (5′-AGAGTTTGATCMTGGCTCAG-3′) and reverse primer 1492r (5′-TACGGYTACCTTGTTACGACTT-3′). The resultant PCR product was purified using the PCR Clean-up System Kit (Promega) and concentration of the purified DNA determined by nanodrop.
Specific detection and quantification of 32 phylogenetically related groups of the human intestinal microbiome were achieved by the HTF-Microbi.Array, an adaption to the Ligase Detection Reaction . DNA probes specific for each of the currently identified bacteria of the intestinal microbiome are embedded on the array slide. Successful hybridisation of the DNA product to the probe results in fluorescence. The fluorescence intensities (IF) were normalised to the ligation control signal and background IF values, removing outlier signals that were 2.5-fold above or below the average of the repeated signals (four repeats of each probe on every array). The results were compared to two healthy control samples which were obtained at the start of the study.
Inflammatory bowel disease
Ingenuity pathway analysis
Interferon regulatory factor 2
Minimum essential media
Nuclear factor kappa-light-chain-enhancer of activated B cells
Peripheral blood mononuclear cells
PAXgene Blood RNA Tube
Reliabilty, maintainability and availability
RNA quality indicator
Signal transducer and activator of transcription 3.
We would like to thank all the volunteers who took part in this study and the companies who generously supplied food for the study, New Zealand King Salmon, Venerdi, Red Seal Natural Health, Plant & Food Research, Cereal Partners Worldwide: Nestle & General Mills, Fonterra, New Zealand Avocado, Matiatia Grove, Vegetables.co.nz and The New Zealand Merino Company. Nutrigenomics New Zealand is a collaboration between The University of Auckland and AgResearch Limited and Plant & Food Research and is funded by the Ministry of Business, Innovation and Employment. The microbota work was supported by REINFORCE and was conducted in Professor Patrizia Brigidi's laboratory at the University of Bologna, Italy.
- Ferguson LR: Potential value of nutrigenomics in Crohn's disease. Nat Rev Gastroenterol Hepatol. 2012, 9 (5): 260-270. 10.1038/nrgastro.2012.41.View ArticlePubMedGoogle Scholar
- Calder PC: Fatty acids and inflammation: the cutting edge between food and pharma. Eur J Pharmacol. 2011, 668 (Suppl 1): S50-58.View ArticlePubMedGoogle Scholar
- Corfield AP, Wallace HM, Probert CS: The molecular biology of inflammatory bowel diseases. Biochem Soc Trans. 2011, 39 (4): 1057-1060. 10.1042/BST0391057.View ArticlePubMedGoogle Scholar
- Serhan CN: The resolution of inflammation: the devil in the flask and in the details. FASEB J. 2011, 25 (5): 1441-1448. 10.1096/fj.11-0502ufm.PubMed CentralView ArticlePubMedGoogle Scholar
- Bakker GC, van Erk MJ, Pellis L, Wopereis S, Rubingh CM, Cnubben NH, Kooistra T, van Ommen B, Hendriks HF: An antiinflammatory dietary mix modulates inflammation and oxidative and metabolic stress in overweight men: a nutrigenomics approach. Am J Clin Nutr. 2010, 91 (4): 1044-1059. 10.3945/ajcn.2009.28822.View ArticlePubMedGoogle Scholar
- Bannenberg G, Serhan CN: Specialized pro-resolving lipid mediators in the inflammatory response: an update. Biochim Biophys Acta. 2010, 1801 (12): 1260-1273. 10.1016/j.bbalip.2010.08.002.PubMed CentralView ArticlePubMedGoogle Scholar
- Gentschew L, Ferguson LR: Role of nutrition and microbiota in susceptibility to inflammatory bowel diseases. Mol Nutr Food Res. 2012, 56 (4): 524-535. 10.1002/mnfr.201100630.View ArticlePubMedGoogle Scholar
- Amre DK, D'Souza S, Morgan K, Seidman G, Lambrette P, Grimard G, Israel D, Mack D, Ghadirian P, Deslandres C, Chotard V, Budai B, Law L, Levy E, Seidman EG: Imbalances in dietary consumption of fatty acids, vegetables, and fruits are associated with risk for Crohn's disease in children. Am J Gastroenterol. 2007, 102 (9): 2016-2025. 10.1111/j.1572-0241.2007.01411.x.View ArticlePubMedGoogle Scholar
- D'Souza S, Levy E, Mack D, Israel D, Lambrette P, Ghadirian P, Deslandres C, Morgan K, Seidman EG, Amre DK: Dietary patterns and risk for Crohn's disease in children. Inflamm Bowel Dis. 2008, 14 (3): 367-373. 10.1002/ibd.20333.View ArticlePubMedGoogle Scholar
- Issa M, Saeian K: Diet in inflammatory bowel disease. Nutr Clin Pract. 2011, 26 (2): 151-154. 10.1177/0884533611400233.View ArticlePubMedGoogle Scholar
- Brown K, DeCoffe D, Molcan E, Gibson DL: Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease. Nutrients. 2012, 4 (8): 1095-1119.PubMed CentralView ArticlePubMedGoogle Scholar
- Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR: Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2007, 104 (34): 13780-13785. 10.1073/pnas.0706625104.PubMed CentralView ArticlePubMedGoogle Scholar
- Greenblum S, Turnbaugh PJ, Borenstein E: Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease. Proc Natl Acad Sci U S A. 2012, 109 (2): 594-599. 10.1073/pnas.1116053109.PubMed CentralView ArticlePubMedGoogle Scholar
- Albenberg LG, Lewis JD, Wu GD: Food and the gut microbiota in inflammatory bowel diseases: a critical connection. Curr Opin Gastroenterol. 2012, 28 (4): 314-320. 10.1097/MOG.0b013e328354586f.View ArticlePubMedGoogle Scholar
- Candela M, Rampelli S, Turroni S, Severgnini M, Consolandi C, De Bellis G, Masetti R, Ricci G, Pession A, Brigidi P: Unbalance of intestinal microbiota in atopic children. BMC Microbiol. 2012, 12: 95-10.1186/1471-2180-12-95.PubMed CentralView ArticlePubMedGoogle Scholar
- Hattori M, Taylor TD: The human intestinal microbiome: a new frontier of human biology. DNA Res. 2009, 16 (1): 1-12. 10.1093/dnares/dsn033.PubMed CentralView ArticlePubMedGoogle Scholar
- Candela M, Biagi E, Maccaferri S, Turroni S, Brigidi P: Intestinal microbiota is a plastic factor responding to environmental changes. Trends Microbiol. 2012, 20 (8): 385-391. 10.1016/j.tim.2012.05.003.View ArticlePubMedGoogle Scholar
- Candela M, Consolandi C, Severgnini M, Biagi E, Castiglioni B, Vitali B, De Bellis G, Brigidi P: High taxonomic level fingerprint of the human intestinal microbiota by Ligase Detection Reaction - Universal Array approach. BMC Microbiol. 2010, 10: 116-10.1186/1471-2180-10-116.PubMed CentralView ArticlePubMedGoogle Scholar
- Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, Nalin R, Jarrin C, Chardon P, Marteau P, Roca J, Dore J: Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut. 2006, 55 (2): 205-211. 10.1136/gut.2005.073817.PubMed CentralView ArticlePubMedGoogle Scholar
- Sokol H, Lay C, Seksik P, Tannock GW: Analysis of bacterial bowel communities of IBD patients: what has it revealed?. Inflamm Bowel Dis. 2008, 14 (6): 858-867. 10.1002/ibd.20392.View ArticlePubMedGoogle Scholar
- Rajilic-Stojanovic M, Heilig HG, Molenaar D, Kajander K, Surakka A, Smidt H, de Vos WM: Development and application of the human intestinal tract chip, a phylogenetic microarray: analysis of universally conserved phylotypes in the abundant microbiota of young and elderly adults. Environ Microbiol. 2009, 11 (7): 1736-1751. 10.1111/j.1462-2920.2009.01900.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Bouwens M, van de Rest O, Dellschaft N, Bromhaar MG, de Groot LC, Geleijnse JM, Muller M, Afman LA: Fish-oil supplementation induces antiinflammatory gene expression profiles in human blood mononuclear cells. Am J Clin Nutr. 2009, 90 (2): 415-424. 10.3945/ajcn.2009.27680.View ArticlePubMedGoogle Scholar
- Esposito K, Di Palo C, Maiorino MI, Petrizzo M, Bellastella G, Siniscalchi I, Giugliano D: Long-term effect of mediterranean-style diet and calorie restriction on biomarkers of longevity and oxidative stress in overweight men. Cardiol Res Pract. 2011, 2011: 293916-PubMed CentralGoogle Scholar
- Esposito K, Kastorini CM, Panagiotakos DB, Giugliano D: Mediterranean diet and weight loss: meta-analysis of randomized controlled trials. Metab Syndr Relat Disord. 2011, 9 (1): 1-12. 10.1089/met.2010.0031.View ArticlePubMedGoogle Scholar
- Kastorini CM, Milionis HJ, Esposito K, Giugliano D, Goudevenos JA, Panagiotakos DB: The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. J Am Coll Cardiol. 2011, 57 (11): 1299-1313. 10.1016/j.jacc.2010.09.073.View ArticlePubMedGoogle Scholar
- Sola R, Fito M, Estruch R, Salas-Salvado J, Corella D, de La Torre R, Munoz MA, Lopez-Sabater Mdel C, Martinez-Gonzalez MA, Aros F, Ruiz-Gutierrez V, Fiol M, Casals E, Wärnberg J, Buil-Cosiales P, Ros E, Konstantinidou V, Lapetra J, Serra-Majem L, Covas MI: Effect of a traditional Mediterranean diet on apolipoproteins B, A-I, and their ratio: a randomized, controlled trial. Atherosclerosis. 2011, 218 (1): 174-180. 10.1016/j.atherosclerosis.2011.04.026.View ArticlePubMedGoogle Scholar
- Nanau R, Neuman M: Nutritional and probiotic supplementation in colitis models. Dig Dis Sci. 2012, 57 (11): 2786-2810. 10.1007/s10620-012-2284-3.View ArticlePubMedGoogle Scholar
- Triggs CM, Munday K, Hu R, Fraser AG, Gearry RB, Barclay ML, Ferguson LR: Dietary factors in chronic inflammation: food tolerances and intolerances of a New Zealand Caucasian Crohn's disease population. Mutat Res. 2010, 690 (1–2): 123-138.View ArticlePubMedGoogle Scholar
- Ellett S, Ferguson IR, Zhu S, Karunasinghe N, Marlow G, Hurley D, Lam WJ, Han DY, Ferguson LR: Foodomics to study efficacy of human dietary interventions: proof of principle study. In Nutrigenomics and Nutrigenetics in Functional Foods and Personalized Nutrition. Edited by Ferguson LR. 2013, Boca Raton, FL: CRC PressView ArticleGoogle Scholar
- Bisoendial RJ, Boekholdt SM, Vergeer M, Stroes ES, Kastelein JJ: C-reactive protein is a mediator of cardiovascular disease. Eur Heart J. 2010, 31 (17): 2087-2091. 10.1093/eurheartj/ehq238.View ArticlePubMedGoogle Scholar
- Karadag F, Kirdar S, Karul AB, Ceylan E: The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. Eur J Intern Med. 2008, 19 (2): 104-108. 10.1016/j.ejim.2007.04.026.View ArticlePubMedGoogle Scholar
- Thomas P, Fenech M: Cytokinesis-block micronucleus cytome assay in lymphocytes. Methods Mol Biol. 2011, 682: 217-234. 10.1007/978-1-60327-409-8_16.View ArticlePubMedGoogle Scholar
- de Graaf AA, Freidig AP, De Roos B, Jamshidi N, Heinemann M, Rullmann JA, Hall KD, Adiels M, van Ommen B: Nutritional systems biology modeling: from molecular mechanisms to physiology. PLoS Comput Biol. 2009, 5 (11): e1000554-10.1371/journal.pcbi.1000554.PubMed CentralView ArticlePubMedGoogle Scholar
- Puiggros F, Sola R, Blade C, Salvado MJ, Arola L: Nutritional biomarkers and foodomic methodologies for qualitative and quantitative analysis of bioactive ingredients in dietary intervention studies. J Chromatogr A. 2011, 1218 (42): 7399-7414. 10.1016/j.chroma.2011.08.051.View ArticlePubMedGoogle Scholar
- Chae M, Kim K, Park S-M, Jang I-S, Seo T, Kim D-M, Kim I-C, Lee J-H, Park J: IRF-2 regulates NF-κB activity by modulating the subcellular localization of NF-κB. Biochem Biophys Res Commun. 2008, 370 (3): 519-524. 10.1016/j.bbrc.2008.03.136.View ArticlePubMedGoogle Scholar
- Sugimoto K: Role of STAT3 in inflammatory bowel disease. World J Gastroenterol. 2008, 14 (33): 5110-5114. 10.3748/wjg.14.5110.PubMed CentralView ArticlePubMedGoogle Scholar
- Li Y, de Haar C, Peppelenbosch MP, van der Woude CJ: New insights into the role of STAT3 in IBD. Inflamm Bowel Dis. 2012, 18 (6): 1177-1183. 10.1002/ibd.21884.View ArticlePubMedGoogle Scholar
- de Mello VD, Kolehmanien M, Schwab U, Pulkkinen L, Uusitupa M: Gene expression of peripheral blood mononuclear cells as a tool in dietary intervention studies: what do we know so far?. Mol Nutr Food Res. 2012, 56 (7): 1160-1172. 10.1002/mnfr.201100685.View ArticlePubMedGoogle Scholar
- Rudkowska I, Ponton A, Jacques H, Lavigne C, Holub BJ, Marette A, Vohl MC: Effects of a supplementation of n-3 polyunsaturated fatty acids with or without fish gelatin on gene expression in peripheral blood mononuclear cells in obese, insulin-resistant subjects. J Nutrigenet Nutrigenomics. 2011, 4 (4): 192-202. 10.1159/000330226.View ArticlePubMedGoogle Scholar
- Rudkowska I, Raymond C, Ponton A, Jacques H, Lavigne C, Holub BJ, Marette A, Vohl MC: Validation of the use of peripheral blood mononuclear cells as surrogate model for skeletal muscle tissue in nutrigenomic studies. OMICS. 2011, 15 (1–2): 1-7.View ArticlePubMedGoogle Scholar
- Bomprezzi R, Ringner M, Kim S, Bittner ML, Khan J, Chen Y, Elkahloun A, Yu A, Bielekova B, Meltzer PS, Martin R, McFarland HF, Trent JM: Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum Mol Genet. 2003, 12 (17): 2191-2199. 10.1093/hmg/ddg221.View ArticlePubMedGoogle Scholar
- Connolly PH, Caiozzo VJ, Zaldivar F, Nemet D, Larson J, Hung SP, Heck JD, Hatfield GW, Cooper DM: Effects of exercise on gene expression in human peripheral blood mononuclear cells. J Appl Physiol. 2004, 97 (4): 1461-1469. 10.1152/japplphysiol.00316.2004.View ArticlePubMedGoogle Scholar
- Dabek J, Kulach A, Wilczok T, Mazurek U, Jakubowski D, Gasior Z: Transcriptional activity of genes encoding interferon gamma (IFNgamma) and its receptor assessed in peripheral blood mononuclear cells in patients with cardiac syndrome X. Inflammation. 2007, 30 (3–4): 125-129.View ArticlePubMedGoogle Scholar
- Rokutan K, Morita K, Masuda K, Tominaga K, Shikishima M, Teshima-Kondo S, Omori T, Sekiyama A: Gene expression profiling in peripheral blood leukocytes as a new approach for assessment of human stress response. J Med Invest. 2005, 52 (3–4): 137-144.View ArticlePubMedGoogle Scholar
- van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002, 347 (25): 1999-2009. 10.1056/NEJMoa021967.View ArticlePubMedGoogle Scholar
- Di Paolo S, Schena A, Stallone G, Grandaliano G, Soccio M, Cerullo G, Gesualdo L, Paolo Schena F: Captopril enhances transforming growth factor (TGF)-beta1 expression in peripheral blood mononuclear cells: a mechanism independent from angiotensin converting enzyme inhibition? A study in cyclosporine-treated kidney-transplanted patients. Transplantation. 2002, 74 (12): 1710-1715.View ArticlePubMedGoogle Scholar
- Fuchs D, Piller R, Linseisen J, Daniel H, Wenzel U: The human peripheral blood mononuclear cell proteome responds to a dietary flaxseed-intervention and proteins identified suggest a protective effect in atherosclerosis. Proteomics. 2007, 7 (18): 3278-3288. 10.1002/pmic.200700096.View ArticlePubMedGoogle Scholar
- Theuwissen E, Plat J, Mensink RP: Consumption of oat beta-glucan with or without plant stanols did not influence inflammatory markers in hypercholesterolemic subjects. Mol Nutr Food Res. 2009, 53 (3): 370-376. 10.1002/mnfr.200800132.View ArticlePubMedGoogle Scholar
- Shelby MD: A report on guidelines for mutagenicity testing. "Report of the UKEMS Sub-Committee on Guidelines for Mutagenicity Testing. Part 1: Basic Test Battery; Minimal Criteria; Professional Standards; Interpretation; Selection of Supplementary Assays," Brian J. Dean (ed). London: UKEMS, 1983. Environ Mutagen. 1983, 5 (6): 941-943. 10.1002/em.2860050617.View ArticleGoogle Scholar
- Heddle JA, Lue CB, Saunders EF, Benz RD: Sensitivity to five mutagens in Fanconi's anemia as measured by the micronucleus method. Cancer Res. 1978, 38 (9): 2983-2988.PubMedGoogle Scholar
- Fenech M: The cytokinesis-block micronucleus technique: a detailed description of the method and its application to genotoxicity studies in human populations. Mutat Res. 1993, 285 (1): 35-44. 10.1016/0027-5107(93)90049-L.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.